New York Times scribe Andrew Pollack takes a careful look at the current trend of making new drugs out of combinations of old therapies. Despite reporting one trial failure last week, CombinatoRx is out in the lead on this one. Researchers at the company are systematically running through the possible combinations of 2,000 generic drugs. But Pozen, Orexigen and other biotechs have combinatorial programs in place as well.
- read the article from The New York Times
Related Articles:
FDA buoys Pozen, accepts of amended response. Report
Orexigen Therapeutics files $86 million IPO. Report